(November 9) The Business Resource For H1N1 Preparis, Inc. today associated the rapid spread of H1N1 pandemic to the high percentage of companies that are not doing enough to prevent its spread in the workplace.
Preparis helps businesses prepare for any threat, including pandemics, terrorism and natural disasters, by delivering services and information to desktops and mobile devices. H1N1 Central is unique in that it is a free, centralized resource featuring information and tools that focus specifically on what businesses need to know and do in order to protect their companies and workforce. www.preparis.com/swineflu/
(November 8) D.C. Vaccine Conference Will Attract Government Policy Makers and Biotech Innovators - FROM: M.E. Garza's Instablog
On Monday and Tuesday of this week, the 7th Annual Vaccines: All Things Considered Conference is taking place in Washington, DC.
Investors should keep an eye on this event, which serves as a one-stop destination for valuable updates and exposure on all aspects of vaccine research, development, regulations, and policy via key, intimate presentations by innovative biotech companies and government regulators. Organizers aim to provide exposure to all avenues of vaccine research, development, regulations and policy and updates on the flu pandemic, bio-defense policy.
(October 28) Pay close attention to CEL SCI (CVM) in the next two weeks... - Dimitrije
CEL SCI scientists have a large portion of speaking time unlike at the ACR convention where they were one amongst hundreds. In attendance will be Industry leaders, academic and government organizations, and the financial community.
This could have an impact on (APT) a manufacturer of N96 respirators future bottom line November 7) White House Urged To Modify 2009 H1N1 Guidance For Healthcare Workers And Issue Moratorium On OSHA Enforcement
Three leading scientific organizations specializing in infectious diseases prevention issued a letter to President Obama expressing their significant concern with current federal guidance concerning the use of personal protective equipment (PPE) by healthcare workers in treating suspected or confirmed cases of 2009 H1N1 influenza.
Federal PPE guidance and requirements issued recently by the Centers for Disease Control and Prevention (CDC) and OSHA include the use of fit-tested N95 respirators by healthcare workers rather than the use of standard surgical masks. According to these organizations--represe... scientists, infectious disease specialists and healthcare professionals dedicated to healthcare quality, safety and infection control--this guidance does not reflect the best available scientific evidence. Their letter to the White House cited two recent studies demonstrating that the use of N95 respirators does not offer additional protection over that provided by the use of surgical masks.
Where there is smoke there is usually fire… (November 7) H1N1: Many Parents, High-Priority Adults Unable To Get Vaccine
A new national poll from Harvard School of Public Health (HSPH) researchers found that a majority of adults who tried to get the H1N1 vaccine for themselves or their children have been unable to do so. The polling was done October 30 to November 1, 2009.
Since the H1N1 flu vaccine became available in October, 17% of American adults, 41% of parents, and 21% of high-priority adults have tried to get it.
Among adults who tried to get it for themselves, 70% were unable to get it. Among parents who tried to get the H1N1 vaccine for their children, 66% were unable to get it. Among high priority adults who tried to get the H1N1 vaccine, 66% were unable to get it.
The poll also shows that some people were not able to find information about the location of available H1N1 flu vaccine. Approximately half who tried to find such information (49%) were unable to find it.
(November 7) Novartis Receives Regulatory Approval In Germany For Celtura®, A Cell Culture-based Influenza A(H1N1) Pandemic Vaccine
Novartis (NVS) announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 mono-valent vaccine, Celtura®. Novartis continues to pursue registration in other major countries, including Japan and Switzerland.
(November 7) CEL-SCI (CVM) To Conduct First Clinical Study Of Investigational LEAPS-H1N1 Treatment For Hospitalized H1N1 Infected Patients
CEL-SCI Corporation (CVM) announced today that an Institutional Review Board of The Johns Hopkins University School of Medicine (Johns Hopkins) has given clearance for the Company's first clinical study to proceed.
This initial study will involve taking blood from hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS H1N1 investigational therapy in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol.
That's OK triple, there is always a welcome sign out here. I am a big fan of stream of coconsciousness - free flow of information… I would hate to see structure inhibit that. I summarize the SF materials in the top part of the Insta as we go along.
(November 6) HHS Orders Intravenous Antiviral Flu Medication To Help Patients Hospitalized With 2009 H1N1
The U.S. Department of Health and Human Services announced contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat hospitalized 2009 H1N1 influenza patients.
To help meet the potential need for IV medications to combat the H1N1 virus, HHS ordered 10,000 treatment courses each from BioCryst (BCRX), Roche (ROG) and GlaxoSmithKline (GSK), totaling $31.5 million. The contracts allow Health and Human Services to place additional orders of up to 30,000 treatment courses with each manufacturer over two years. Roche manufactures Tamiflu; GlaxoSmithKline, Relenza, and BioCryst manufactures Peramivir.
Because there are no Food and Drug Administration (FDA) -approved antiviral medications that can be administered intravenously to treat influenza, the FDA issued an emergency use authorization on Oct. 23 to allow use of intravenous Peramivir, an investigational antiviral drug in the class of drugs known as neuraminidase inhibitors.
The HHS orders for intravenous oseltamivir (Tamiflu) and intravenous zanamivir (Relenza), also neuraminidase inhibitors, are predicated on FDA emergency use authorization for these medications.
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
(November 9) The Business Resource For H1N1
Preparis, Inc. today associated the rapid spread of H1N1 pandemic to the high percentage of companies that are not doing enough to prevent its spread in the workplace.
www.medicalnewstoday.c...
Preparis helps businesses prepare for any threat, including pandemics, terrorism and natural disasters, by delivering services and information to desktops and mobile devices. H1N1 Central is unique in that it is a free, centralized resource featuring information and tools that focus specifically on what businesses need to know and do in order to protect their companies and workforce.
www.preparis.com/swineflu/
The Hindenburg Omen (Extended) [View instapost]
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
On Monday and Tuesday of this week, the 7th Annual Vaccines: All Things Considered Conference is taking place in Washington, DC.
Investors should keep an eye on this event, which serves as a one-stop destination for valuable updates and exposure on all aspects of vaccine research, development, regulations, and policy via key, intimate presentations by innovative biotech companies and government regulators. Organizers aim to provide exposure to all avenues of vaccine research, development, regulations and policy and updates on the flu pandemic, bio-defense policy.
seekingalpha.com/insta...
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
CEL SCI scientists have a large portion of speaking time unlike at the ACR convention where they were one amongst hundreds. In attendance will be Industry leaders, academic and government organizations, and the financial community.
seekingalpha.com/insta...
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
November 7) White House Urged To Modify 2009 H1N1 Guidance For Healthcare Workers And Issue Moratorium On OSHA Enforcement
Three leading scientific organizations specializing in infectious diseases prevention issued a letter to President Obama expressing their significant concern with current federal guidance concerning the use of personal protective equipment (PPE) by healthcare workers in treating suspected or confirmed cases of 2009 H1N1 influenza.
Federal PPE guidance and requirements issued recently by the Centers for Disease Control and Prevention (CDC) and OSHA include the use of fit-tested N95 respirators by healthcare workers rather than the use of standard surgical masks. According to these organizations--represe... scientists, infectious disease specialists and healthcare professionals dedicated to healthcare quality, safety and infection control--this guidance does not reflect the best available scientific evidence. Their letter to the White House cited two recent studies demonstrating that the use of N95 respirators does not offer additional protection over that provided by the use of surgical masks.
www.medicalnewstoday.c...
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
(November 7) H1N1: Many Parents, High-Priority Adults Unable To Get Vaccine
A new national poll from Harvard School of Public Health (HSPH) researchers found that a majority of adults who tried to get the H1N1 vaccine for themselves or their children have been unable to do so. The polling was done October 30 to November 1, 2009.
Since the H1N1 flu vaccine became available in October, 17% of American adults, 41% of parents, and 21% of high-priority adults have tried to get it.
Among adults who tried to get it for themselves, 70% were unable to get it. Among parents who tried to get the H1N1 vaccine for their children, 66% were unable to get it. Among high priority adults who tried to get the H1N1 vaccine, 66% were unable to get it.
The poll also shows that some people were not able to find information about the location of available H1N1 flu vaccine. Approximately half who tried to find such information (49%) were unable to find it.
www.medicalnewstoday.c...
The Real Job Loss Story: Death of Small Business [View article]
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
The Hindenburg Omen (Extended) [View instapost]
I hope you have a safe trip.
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
Novartis (NVS) announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 mono-valent vaccine, Celtura®. Novartis continues to pursue registration in other major countries, including Japan and Switzerland.
www.medicalnewstoday.c...
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
CEL-SCI Corporation (CVM) announced today that an Institutional Review Board of The Johns Hopkins University School of Medicine (Johns Hopkins) has given clearance for the Company's first clinical study to proceed.
This initial study will involve taking blood from hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS H1N1 investigational therapy in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol.
www.medicalnewstoday.c...
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
"This is a raid not a commitment"
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
Swine Flu News Concentrator (November 5 - 13 Part 3) [View instapost]
The U.S. Department of Health and Human Services announced contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat hospitalized 2009 H1N1 influenza patients.
To help meet the potential need for IV medications to combat the H1N1 virus, HHS ordered 10,000 treatment courses each from BioCryst (BCRX), Roche (ROG) and GlaxoSmithKline (GSK), totaling $31.5 million. The contracts allow Health and Human Services to place additional orders of up to 30,000 treatment courses with each manufacturer over two years. Roche manufactures Tamiflu; GlaxoSmithKline, Relenza, and BioCryst manufactures Peramivir.
Because there are no Food and Drug Administration (FDA) -approved antiviral medications that can be administered intravenously to treat influenza, the FDA issued an emergency use authorization on Oct. 23 to allow use of intravenous Peramivir, an investigational antiviral drug in the class of drugs known as neuraminidase inhibitors.
The HHS orders for intravenous oseltamivir (Tamiflu) and intravenous zanamivir (Relenza), also neuraminidase inhibitors, are predicated on FDA emergency use authorization for these medications.
www.medicalnewstoday.c...